European urology oncology
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
Andrew J Armstrong, Fred Saad, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Craig Gedye, Gary L Buchschacher, Ji Youl Lee, Urban Emmenegger, Jiří Navrátil, Juan Antonio Virizuela, Anibal Salazar, Denis Maillet, Hiroji Uemura, Christian Hosius
Published: 202510.1016/j.euo.2025.09.010
Abstract
BACKGROUND AND OBJECTIVE: The phase 3 PROpel study showed a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) with olaparib + abiraterone versus placebo + abiraterone in the first-line se…
Preview only. Read the full abstract at the source